Breaking News Instant updates and real-time market news.

LUNG

Pulmonx

$34.00 /

+2.66 (+8.49%)

05:01
12/08/21
12/08
05:01
12/08/21
05:01

Pulmonx upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler analyst Jason Bednar upgraded Pulmonx to Overweight from Neutral with an unchanged price target of $45. The recent selloff in the shares discounts the risk factors and makes the setup attractive considering the company's revenue growth potential, Bednar tells investors in a research note. The analyst highlights limited visibility into improvements in procedure cadence due to still-elevated COVID hospitalizations and near-term unknowns with ICU staffing levels as the risks. New account additions continuing at their recent pace and a resumption of account productivity improvements in mid-2022 should place Pulmonx's revenue growth at the upper-end of high-growth medical technology players, but its valuation is now closer to in line with peers, says Bednar. He recommends "stepping in at current levels and would be more aggressive buyers on further pullbacks."

  • 13

    Jul

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
FDA approves Novartis' Kymriah CAR-T cell therapy for r/r follicular lymphoma » 13:23
05/28/22
05/28
13:23
05/28/22
13:23
NVS

Novartis

$91.46 /

+0.205 (+0.22%)

Novartis announced the US…

Novartis announced the US Food and Drug Administration has granted accelerated approval for Kymriah for the treatment of adult patients with relapsed or refractory, or r/r, follicular lymphoma, or FL, after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). The approval is based on data from the Phase II ELARA trial, a single-arm, open-label trial, in which 90 patients were evaluated for efficacy with a median follow-up of approximately 17 months. Eighty-six percent of patients treated with Kymriah achieved a response including 68% who experienced a complete response, the company noted. "Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings," the company stated.

ShowHide Related Items >><<
NVS Novartis
$91.46 /

+0.205 (+0.22%)

NVS Novartis
$91.46 /

+0.205 (+0.22%)

05/13/22 Piper Sandler
Point Biopharma price target lowered to $14 from $17 at Piper Sandler
05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
05/09/22 Wolfe Research
Novartis downgraded to Peer Perform from Outperform at Wolfe Research
05/06/22 Morgan Stanley
Novartis price target raised to CHF 94 from CHF 90 at Morgan Stanley
NVS Novartis
$91.46 /

+0.205 (+0.22%)

NVS Novartis
$91.46 /

+0.205 (+0.22%)

NVS Novartis
$91.46 /

+0.205 (+0.22%)

Hot Stocks
Bristol-Myers announces FDA approves two Opdivo-based regimens » 13:21
05/28/22
05/28
13:21
05/28/22
13:21
BMY

Bristol-Myers

$76.16 /

-1.45 (-1.87%)

Bristol Myers Squibb…

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has approved both Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo plus Yervoy as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, or ESCC, regardless of PD-L1 status. The approvals are based on the Phase 3 CheckMate -648 trial, which evaluated Opdivo in combination with chemotherapy and Opdivo plus Yervoy, each compared to chemotherapy alone, and was the largest Phase 3 trial of an immunotherapy in first-line ESCC, the company stated. Adam Lenkowsky, senior vice president and general manager, U.S., Cardiovascular, Immunology, Oncology, Bristol Myers Squibb, added, "Today's approvals bring two first-line immunotherapy-based treatment options at once, Opdivo in combination with chemotherapy and Opdivo plus Yervoy as the first dual immunotherapy option, to newly diagnosed patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, further building on the role of Opdivo-based regimens in upper gastroesophageal cancers."

ShowHide Related Items >><<
BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

05/26/22 Citi
Bristol-Myers price target raised to $90 from $75 at Citi
05/17/22 Wells Fargo
Bristol-Myers price target raised to $70 from $65 at Wells Fargo
05/12/22 Piper Sandler
Ventyx Biosciences 'top pick' heading into data-rich Q3, says Piper Sandler
05/02/22 Truist
Bristol-Myers price target raised to $81 from $76 at Truist
BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

Periodicals
Boeing hasn't delivered on jets or other recovery requisites, Barron's says » 10:41
05/28/22
05/28
10:41
05/28/22
10:41
BA

Boeing

$132.23 /

+4.505 (+3.53%)

Boeing's badly…

Boeing's badly beaten-up stock might be nearly as weak as it will get, and the big drop seems to have attracted some interest in the shares recently, Al Root writes in this week's edition of Barron's. At this point, Boeing's task is simple-it needs to stop the bleeding. For that to happen, the company needs to deliver more 737 MAX jets to customers and win permission to resume deliveries of the 787 twin-aisle jet. Reference Link

ShowHide Related Items >><<
BA Boeing
$132.23 /

+4.505 (+3.53%)

BA Boeing
$132.23 /

+4.505 (+3.53%)

05/24/22 JPMorgan
Boeing goal remains deliveries despite questions, says JPMorgan
05/20/22 Susquehanna
Boeing price target lowered to $192 from $193 at Susquehanna
05/17/22 BofA
Boeing price target lowered to $150 from $180 at BofA
05/17/22 JPMorgan
Boeing report 'not as stark' as market's read, says JPMorgan
BA Boeing
$132.23 /

+4.505 (+3.53%)

BA Boeing
$132.23 /

+4.505 (+3.53%)

BA Boeing
$132.23 /

+4.505 (+3.53%)

BA Boeing
$132.23 /

+4.505 (+3.53%)

Periodicals
Under Armour transformation will take much longer to play out, Barron's says » 10:39
05/28/22
05/28
10:39
05/28/22
10:39
UA

Under Armour

$9.38 /

+0.245 (+2.68%)

, UAA

Under Armour

$10.33 /

+0.23 (+2.28%)

There were a lot of…

There were a lot of reasons to be optimistic about Under Armour in April but then May happened, with much of the decline in the stock due to its own missteps, Teresa Rivas writes in this week's edition of Barron's. The company delivered a surprise loss at the start of the month, hurt by supply-chain woes and pandemic-related lockdowns in China. Then last week, it announced the departure of CEO Patrik Frisk, who had led the company's turnaround efforts over the past two years, the author notes. While Under Armour's transformation might not be out of the question, it inevitably looks as if that will now take much longer to play out than Rivas originally thought, at a time when the market has little in the way of patience for retailers that miss the mark. Reference Link

ShowHide Related Items >><<
UAA Under Armour
$10.33 /

+0.23 (+2.28%)

UA Under Armour
$9.38 /

+0.245 (+2.68%)

UA Under Armour
$9.38 /

+0.245 (+2.68%)

05/23/22 Citi
Under Armour downgraded to Neutral from Buy at Citi
05/19/22 Morgan Stanley
Under Armour downgraded to Equal Weight from Overweight at Morgan Stanley
05/10/22 Barclays
Under Armour price target lowered to $14 from $22 at Barclays
05/09/22 B. Riley
Under Armour price target lowered to $11 from $18 at B. Riley
UAA Under Armour
$10.33 /

+0.23 (+2.28%)

05/19/22 Williams Trading
Under Armour downgraded to Hold from Buy at Williams Trading
05/11/22 Argus
Under Armour price target lowered to $15 from $19 at Argus
UA Under Armour
$9.38 /

+0.245 (+2.68%)

UA Under Armour
$9.38 /

+0.245 (+2.68%)

UA Under Armour
$9.38 /

+0.245 (+2.68%)

UAA Under Armour
$10.33 /

+0.23 (+2.28%)

UA Under Armour
$9.38 /

+0.245 (+2.68%)

Periodicals
Snowflake stock finally looks attractive, Barron's says » 10:34
05/28/22
05/28
10:34
05/28/22
10:34
SNOW

Snowflake

$129.80 /

+3.55 (+2.81%)

It's been more than…

It's been more than 600 days since Snowflake came public in one of the hottest initial public offerings of the pandemic era. It turned out to be a winding, nearly two-year road back to the starting line, Eric J. Savitz writes in this week's edition of Barron's. For investors, there's now an opportunity to make a sharply discounted bet on what remains one of the most impressive growth stories in software, he adds. Snowflake shares peaked at just over $400 last November, but it has been all downhill from there. The stock has swooned 70% over the last six months. This past week, shares briefly traded below their $120 IPO price for the first time ever, the publication notes. While still not a value play, Snowflake now trades at a much more reasonable 13 times expected fiscal 2024 revenue of $3 billion - with a growth rate unmatched in software. The outlook remains strong, and the stock has been de-risked, Savitz writes. Reference Link

ShowHide Related Items >><<
SNOW Snowflake
$129.80 /

+3.55 (+2.81%)

SNOW Snowflake
$129.80 /

+3.55 (+2.81%)

05/26/22 Truist
Snowflake price target lowered to $200 from $300 at Truist
05/26/22 JMP Securities
Snowflake price target lowered to $180 from $385 at JMP Securities
05/26/22 Evercore ISI
Snowflake price target lowered to $175 from $250 at Evercore ISI
05/26/22 Loop Capital
Snowflake price target lowered to $180 from $370 at Loop Capital
SNOW Snowflake
$129.80 /

+3.55 (+2.81%)

SNOW Snowflake
$129.80 /

+3.55 (+2.81%)

SNOW Snowflake
$129.80 /

+3.55 (+2.81%)

SNOW Snowflake
$129.80 /

+3.55 (+2.81%)

Periodicals
Chewy earnings might not be so great but stock could take off, Barron's says » 10:30
05/28/22
05/28
10:30
05/28/22
10:30
CHWY

Chewy

$27.11 /

+1.57 (+6.15%)

Chewy is set to report…

Chewy is set to report earnings this coming Wednesday. It's expected to report a loss of 10 cents a share on sales of $2.41 billion, and a profit on adjusted earnings before interest, taxes, amortization, and depreciation-or Ebitda-of $6 million. That could be optimistic, Ben Levisohn writes in this week's edition of Barron's. Regardless, Chewy is hoping that it will ultimately have added more subscribers than it lost, the author notes. Reference Link

ShowHide Related Items >><<
CHWY Chewy
$27.11 /

+1.57 (+6.15%)

CHWY Chewy
$27.11 /

+1.57 (+6.15%)

05/25/22 Deutsche Bank
Chewy price target lowered to $35 from $55 at Deutsche Bank
05/24/22 Barclays
Chewy price target lowered to $26 from $41 at Barclays
05/20/22 Jefferies
Pet specialty retail selloff overdone, says Jefferies
04/13/22 JPMorgan
Chewy customer growth to reaccelerate in late 2022, says JPMorgan
CHWY Chewy
$27.11 /

+1.57 (+6.15%)

CHWY Chewy
$27.11 /

+1.57 (+6.15%)

CHWY Chewy
$27.11 /

+1.57 (+6.15%)

CHWY Chewy
$27.11 /

+1.57 (+6.15%)

Periodicals
Buy Bristol-Myers, rally just getting started, Barron's says » 10:27
05/28/22
05/28
10:27
05/28/22
10:27
BMY

Bristol-Myers

$76.16 /

-1.45 (-1.87%)

Bristol-Myers Squibb has…

Bristol-Myers Squibb has been a bright spot in a very tough market-and the stock's move higher may just be getting started, Jacob Sonenshine writes in this week's edition of Barron's. While the Revlimid patent concerns haven't gone away, the company now seems better prepared to weather the transition, the author notes. While the stock has gained this year, its shares still look cheap, he adds, arguing that after years of waiting, Bristol appears poised to be a winner once again. Reference Link

ShowHide Related Items >><<
BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

05/26/22 Citi
Bristol-Myers price target raised to $90 from $75 at Citi
05/17/22 Wells Fargo
Bristol-Myers price target raised to $70 from $65 at Wells Fargo
05/12/22 Piper Sandler
Ventyx Biosciences 'top pick' heading into data-rich Q3, says Piper Sandler
05/02/22 Truist
Bristol-Myers price target raised to $81 from $76 at Truist
BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

BMY Bristol-Myers
$76.16 /

-1.45 (-1.87%)

Periodicals
Alphabet, Meta among bargain stocks to buy now, Barron's says » 10:15
05/28/22
05/28
10:15
05/28/22
10:15
GOOGL

Alphabet Class A

$2,246.13 /

+90.575 (+4.20%)

, GOOG

Alphabet

$2,255.66 /

+89.655 (+4.14%)

, LRCX

Lam Research

$531.40 /

+22.1 (+4.34%)

, FB

Meta Platforms

$195.06 /

+3.55 (+1.85%)

, MU

Micron

$73.31 /

+2.71 (+3.84%)

, NFLX

Netflix

$195.19 /

+3.88 (+2.03%)

, TER

Teradyne

$109.42 /

+4.52 (+4.31%)

With about two-thirds of…

With about two-thirds of the stocks in the S&P 500 down more than 20% from their all-time highs and the index itself down 15%, many stocks are on sale, Al Root writes in this week's edition of Barron's. But the stock market isn't like a clothing store, where bargains are happily scooped up, even if not all of them will look as good when you get home. Instead, when stocks are falling, many investors find it difficult to pull the trigger, fearful they'll pick a dud that only adds to the pain that's already afflicting their portfolios. But there are opportunities amid the rubble, the author notes. Among those who fit the bill, Root says, are Alphabet (GOOGL), Lam Research (LRCX), Meta Platforms (FB), Micron (MU), Netflix (NFLX), and Teradyne (TER). Reference Link

ShowHide Related Items >><<
TER Teradyne
$109.42 /

+4.52 (+4.31%)

NFLX Netflix
$195.19 /

+3.88 (+2.03%)

MU Micron
$73.31 /

+2.71 (+3.84%)

LRCX Lam Research
$531.40 /

+22.1 (+4.34%)

GOOGL Alphabet Class A
$2,246.13 /

+90.575 (+4.20%)

FB Meta Platforms
$195.06 /

+3.55 (+1.85%)

GOOGL Alphabet Class A
$2,246.13 /

+90.575 (+4.20%)

05/24/22 Jefferies
Alphabet price target lowered to $3,100 from $3,400 at Jefferies
05/24/22 BofA
Snap price target lowered to $30 from $50 at BofA
05/24/22 KeyBanc
Snap price target lowered to $27 from $45 at KeyBanc
05/24/22 Piper Sandler
Snap price target lowered to $30 from $50 at Piper Sandler
GOOG Alphabet
$2,255.66 /

+89.655 (+4.14%)

LRCX Lam Research
$531.40 /

+22.1 (+4.34%)

05/26/22 Piper Sandler
Lam Research price target lowered to $567 from $596 at Piper Sandler
05/18/22 Jefferies
Information Technology sector upgraded to Bullish at Jefferies
04/22/22 Jefferies
Lam Research price target lowered to $670 from $869 at Jefferies
04/21/22 Morgan Stanley
Lam Research price target lowered to $625 from $730 at Morgan Stanley
FB Meta Platforms
$195.06 /

+3.55 (+1.85%)

05/24/22 Jefferies
Meta Platforms price target lowered to $310 from $330 at Jefferies
MU Micron
$73.31 /

+2.71 (+3.84%)

05/17/22 Piper Sandler
Piper moves to 'more positive stance' on semiconductor stocks
05/13/22 Evercore ISI
Evercore reiterates Outperform rating, $90 target on Micron after analyst day
05/13/22 Wells Fargo
Micron shares deserve rerating, says Wells Fargo
05/13/22 Citi
Citi reiterates $120 price target on Micron after analsyt meeting
NFLX Netflix
$195.19 /

+3.88 (+2.03%)

05/24/22 Citi
Netflix shares do not have 'natural investor base,' says Citi
05/16/22 Wedbush
Wedbush sees Netflix positioned to exceed Q2 guidance, upgrades to Outperform
05/16/22 Wedbush
Netflix upgraded to Outperform from Neutral at Wedbush
05/16/22 Stifel
Trade Desk upgraded to Buy from Hold at Stifel
TER Teradyne
$109.42 /

+4.52 (+4.31%)

05/26/22 Piper Sandler
Teradyne price target lowered to $127 from $163 at Piper Sandler
03/27/22 Goldman Sachs
Teradyne downgraded to Neutral from Buy at Goldman Sachs
03/03/22 Morgan Stanley
Morgan Stanley downgrades '2023 story' Teradyne to Equal Weight
03/03/22 Morgan Stanley
Teradyne downgraded to Equal Weight from Overweight at Morgan Stanley
TER Teradyne
$109.42 /

+4.52 (+4.31%)

NFLX Netflix
$195.19 /

+3.88 (+2.03%)

MU Micron
$73.31 /

+2.71 (+3.84%)

LRCX Lam Research
$531.40 /

+22.1 (+4.34%)

GOOGL Alphabet Class A
$2,246.13 /

+90.575 (+4.20%)

FB Meta Platforms
$195.06 /

+3.55 (+1.85%)

NFLX Netflix
$195.19 /

+3.88 (+2.03%)

MU Micron
$73.31 /

+2.71 (+3.84%)

LRCX Lam Research
$531.40 /

+22.1 (+4.34%)

GOOGL Alphabet Class A
$2,246.13 /

+90.575 (+4.20%)

GOOG Alphabet
$2,255.66 /

+89.655 (+4.14%)

FB Meta Platforms
$195.06 /

+3.55 (+1.85%)

TER Teradyne
$109.42 /

+4.52 (+4.31%)

NFLX Netflix
$195.19 /

+3.88 (+2.03%)

MU Micron
$73.31 /

+2.71 (+3.84%)

LRCX Lam Research
$531.40 /

+22.1 (+4.34%)

GOOGL Alphabet Class A
$2,246.13 /

+90.575 (+4.20%)

FB Meta Platforms
$195.06 /

+3.55 (+1.85%)

TER Teradyne
$109.42 /

+4.52 (+4.31%)

NFLX Netflix
$195.19 /

+3.88 (+2.03%)

MU Micron
$73.31 /

+2.71 (+3.84%)

LRCX Lam Research
$531.40 /

+22.1 (+4.34%)

GOOGL Alphabet Class A
$2,246.13 /

+90.575 (+4.20%)

GOOG Alphabet
$2,255.66 /

+89.655 (+4.14%)

FB Meta Platforms
$195.06 /

+3.55 (+1.85%)

Conference/Events
1-800-Flowers.com management to meet virtually with Oppenheimer » 04:55
05/28/22
05/28
04:55
05/28/22
04:55
FLWS

1-800-Flowers.com

$9.76 /

+0.015 (+0.15%)

Virtual Meeting to be…

Virtual Meeting to be held on May 28 hosted by Oppenheimer.

ShowHide Related Items >><<
FLWS 1-800-Flowers.com
$9.76 /

+0.015 (+0.15%)

FLWS 1-800-Flowers.com
$9.76 /

+0.015 (+0.15%)

04/29/22 Benchmark
1-800-Flowers.com price target lowered to $17 from $26 at Benchmark
04/28/22 Craig-Hallum
Craig-Hallum downgrades 1-800-Flowers, says things could get worse before better
04/28/22 Craig-Hallum
1-800-Flowers.com downgraded to Hold from Buy at Craig-Hallum
03/17/22 DA Davidson
1-800-Flowers.com downgraded to Neutral from Buy at DA Davidson
FLWS 1-800-Flowers.com
$9.76 /

+0.015 (+0.15%)

FLWS 1-800-Flowers.com
$9.76 /

+0.015 (+0.15%)

Conference/Events
Integra LifeSciences management to meet virtually with Oppenheimer » 04:55
05/28/22
05/28
04:55
05/28/22
04:55
IART

Integra LifeSciences

$62.09 /

+0.69 (+1.12%)

Virtual Meeting to be…

Virtual Meeting to be held on May 28 hosted by Oppenheimer.

ShowHide Related Items >><<
IART Integra LifeSciences
$62.09 /

+0.69 (+1.12%)

IART Integra LifeSciences
$62.09 /

+0.69 (+1.12%)

05/17/22 Citi
Integra LifeSciences price target lowered to $67 from $70 at Citi
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Integra LifeSciences assumed at Hold from Buy at Truist
02/24/22 JPMorgan
JPMorgan lays out potential takeover targets in medical technology
IART Integra LifeSciences
$62.09 /

+0.69 (+1.12%)

IART Integra LifeSciences
$62.09 /

+0.69 (+1.12%)

General news
Treasury Market Summary » 21:25
05/27/22
05/27
21:25
05/27/22
21:25
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: Risk appetite continued to surge with strong gains across the board on the session, and helping drive the major indexes sharply higher on the week. Trading was on the lighter side, however, ahead of the long Memorial Day weekend. Worries that an aggressive FOMC policy posture with officials intent on destroying growth to curb inflation have been dissipating. Fedspeak, beginning with Chair Powell, has confirmed that a 75 bp hike is not on the table for now, has helped stabilize investor sentiment and encourage bargain hunters. The drop in yields on the month has supported too. The NASDAQ ended the day with a 3.3% pop, with the S&P 500 up 2.47%, while the Dow rallied 1.76%. The Dow snapped an 8-week losing streak, with the S&P 500 and NASDAQ recovered from 7 straight weeks of losses. For the week, the indexes were over 6% firmer. the week's gain to 6.84%. Treasuries were mixed after an abbreviated session with the front end underperforming slightly. The 2-year rose 1.2 bps to 2.475%, while the 10-year closed 1 bp richer at 2.738%. The dollar index finished at 101.63, recovering from an overnight drop to 101.43, but down from the intraday high of 101.93. Data included weaker than expected consumer sentiment, a solid gain in consumer spending, a slowing in y/y PCE prices, and a narrowing in the goods trade deficit.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Syndicate
SuperCom files to sell 5.65M ordinary shares for holders  17:39
05/27/22
05/27
17:39
05/27/22
17:39
SPCB

SuperCom

/

+

 
ShowHide Related Items >><<
SPCB SuperCom
/

+

SPCB SuperCom
/

+

Syndicate
Olympic Steel files $200M mixed securities shelf  17:38
05/27/22
05/27
17:38
05/27/22
17:38
ZEUS

Olympic Steel

$36.33 /

-0.29 (-0.79%)

 
ShowHide Related Items >><<
ZEUS Olympic Steel
$36.33 /

-0.29 (-0.79%)

ZEUS Olympic Steel
$36.33 /

-0.29 (-0.79%)

Syndicate
Rain Therapeutics files automatic mixed securities shelf  17:37
05/27/22
05/27
17:37
05/27/22
17:37
RAIN

Rain Therapeutics

$2.50 /

+0.19 (+8.23%)

 
ShowHide Related Items >><<
RAIN Rain Therapeutics
$2.50 /

+0.19 (+8.23%)

RAIN Rain Therapeutics
$2.50 /

+0.19 (+8.23%)

05/27/22 Piper Sandler
Rain Therapeutics price target lowered to $12 from $26 at Piper Sandler
03/31/22 Oppenheimer
Rain Therapeutics initiated with an Outperform at Oppenheimer
01/03/22 Guggenheim
Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
11/10/21 Piper Sandler
Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
RAIN Rain Therapeutics
$2.50 /

+0.19 (+8.23%)

Hot Stocks
Akerna to implement plan to reduce workforce » 17:33
05/27/22
05/27
17:33
05/27/22
17:33
KERN

Akerna

/

+

Akerna announced that the…

Akerna announced that the company is implementing a plan to reduce its workforce and operating costs in order to focus its resources, accelerate its path to profitability, and create stakeholder value. The company anticipates reporting $690,000 in total costs in its second quarter to implement the reduction in force, including the following cost elements: $630,000 in severance and associated payroll taxes; $40,000 in legal costs; and $20,000 in employee insurance benefits. Of the total cost, $440,000 in salaries, payroll taxes and benefits costs would have been reported in its second quarter if the reduction in force had not been implemented. "Our sales performance in 2022 has thus far met our expectations. We believe we are showing signs of progress with revenue now at a run rate of $27m at last filing," commented Jessica Billingsley, Akerna's Chief Executive Officer. "While we believe we can continue to grow revenue and continue to reduce expenses over time, we have made the decision to focus our initiatives on our enterprise business and new market expansion of our SMB business, at least until the market conditions and the regulatory environment are in more favorable territory. We can see a path to positive cash flows and profitability, and the board and the management team are committed to getting there on an accelerated timetable. While we continue to deal with liquidity concerns, our headcount reduction and additional cost savings measures represent a material annual cost savings. As part of this restructure, executive leadership team has also collectively agreed to a 25% reduction in salary to help support the company's cost savings initiatives. As we noted on our last earnings call, bookings have been strong and our CARR is $21.1 million, and we are looking to continue to grow our top-line through a combination of enterprise wins as well as the opportunity we see in new market expansion from the SMB side of the business," added Ms. Billingsley.

ShowHide Related Items >><<
KERN Akerna
/

+

KERN Akerna
/

+

05/11/22 Alliance Global Partners
Akerna downgraded to Neutral from Buy at Alliance Global Partners
05/11/22 H.C. Wainwright
Akerna price target lowered to $1.50 from $2.50 at H.C. Wainwright
03/22/22 Lake Street
Akerna downgraded to Hold from Buy at Lake Street
03/22/22 Alliance Global Partners
Akerna price target lowered to $2.50 from $5 at Alliance Global Partners
KERN Akerna
/

+

Hot Stocks
Northrop Grumman awarded $254.42M Navy contract modification » 17:21
05/27/22
05/27
17:21
05/27/22
17:21
NOC

Northrop Grumman

$470.76 /

+5.37 (+1.15%)

Northrop Grumman was…

Northrop Grumman was awarded a $254.42M firm-fixed-price modification to a previously awarded contract to exercise an option for production of Surface Electronic Warfare Improvement Program Block 3 Hemisphere systems. Work is expected to be completed by September 2025. FY22 other procurement funds in the amount of $152.65M and FY22 shipbuilding and conversion funds in the amount of $101.77M will be obligated at time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting authority.

ShowHide Related Items >><<
NOC Northrop Grumman
$470.76 /

+5.37 (+1.15%)

NOC Northrop Grumman
$470.76 /

+5.37 (+1.15%)

05/12/22 Argus
Northrop Grumman price target raised to $495 from $420 at Argus
04/29/22 UBS
Northrop Grumman price target raised to $450 from $410 at UBS
03/29/22 Jefferies
Northrop among biggest beneficiaries of DoD budget request, says Jefferies
03/07/22 Wells Fargo
Northrop Grumman price target raised to $472 from $390 at Wells Fargo
NOC Northrop Grumman
$470.76 /

+5.37 (+1.15%)

NOC Northrop Grumman
$470.76 /

+5.37 (+1.15%)

NOC Northrop Grumman
$470.76 /

+5.37 (+1.15%)

NOC Northrop Grumman
$470.76 /

+5.37 (+1.15%)

Hot Stocks
Raytheon Technologies awarded $624.6M Army contract modification » 17:17
05/27/22
05/27
17:17
05/27/22
17:17
RTX

Raytheon Technologies

$96.67 /

+1.735 (+1.83%)

Raytheon was awarded a…

Raytheon was awarded a $624.6M modification to contract for the procurement of Stinger missiles and associated equipment. Work locations and funding will be determined with each order, with an estimated completion date of June 30, 2026. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
RTX Raytheon Technologies
$96.67 /

+1.735 (+1.83%)

RTX Raytheon Technologies
$96.67 /

+1.735 (+1.83%)

04/27/22 Argus
Raytheon Technologies price target raised to $112 from $100 at Argus
04/27/22 Cowen
Raytheon Technologies price target raised to $120 from $115 at Cowen
04/08/22 RBC Capital
Raytheon Technologies initiated with an Outperform at RBC Capital
03/29/22 Jefferies
Northrop among biggest beneficiaries of DoD budget request, says Jefferies
RTX Raytheon Technologies
$96.67 /

+1.735 (+1.83%)

RTX Raytheon Technologies
$96.67 /

+1.735 (+1.83%)

RTX Raytheon Technologies
$96.67 /

+1.735 (+1.83%)

RTX Raytheon Technologies
$96.67 /

+1.735 (+1.83%)

Syndicate
Entera Bio files to sell 3.76M ordinary shares for holders  17:13
05/27/22
05/27
17:13
05/27/22
17:13
ENTX

Entera Bio

$2.28 /

+0.12 (+5.56%)

 
ShowHide Related Items >><<
ENTX Entera Bio
$2.28 /

+0.12 (+5.56%)

ENTX Entera Bio
$2.28 /

+0.12 (+5.56%)

01/24/22 B. Riley
Entera Bio price target lowered to $6 from $11 at B. Riley
01/06/22 B. Riley
B. Riley 'puzzled' by Entera Bio selloff after FDA agreement
10/07/21 B. Riley
Entera Bio price target lowered to $11 from $14 at B. Riley
06/24/21 B. Riley
Entera Bio price target raised to $14 from $9 at B. Riley
ENTX Entera Bio
$2.28 /

+0.12 (+5.56%)

Syndicate
Entera Bio files $100M mixed securities shelf  17:10
05/27/22
05/27
17:10
05/27/22
17:10
ENTX

Entera Bio

$2.28 /

+0.12 (+5.56%)

 
ShowHide Related Items >><<
ENTX Entera Bio
$2.28 /

+0.12 (+5.56%)

ENTX Entera Bio
$2.28 /

+0.12 (+5.56%)

01/24/22 B. Riley
Entera Bio price target lowered to $6 from $11 at B. Riley
01/06/22 B. Riley
B. Riley 'puzzled' by Entera Bio selloff after FDA agreement
10/07/21 B. Riley
Entera Bio price target lowered to $11 from $14 at B. Riley
06/24/21 B. Riley
Entera Bio price target raised to $14 from $9 at B. Riley
ENTX Entera Bio
$2.28 /

+0.12 (+5.56%)

Hot Stocks
Range Resources CFO sells $1.8M in common stock » 17:08
05/27/22
05/27
17:08
05/27/22
17:08
RRC

Range Resources

$36.15 /

+1.4551 (+4.19%)

In a regulatory filing,…

In a regulatory filing, Range Resources disclosed that its CFO Mark Scucchi sold 55K shares of common stock on May 25th in a total transaction of $1.8M.

ShowHide Related Items >><<
RRC Range Resources
$36.15 /

+1.4551 (+4.19%)

RRC Range Resources
$36.15 /

+1.4551 (+4.19%)

04/25/22 Susquehanna
Range Resources price target raised to $34 from $24 at Susquehanna
04/21/22 Truist
Range Resources price target raised to $37 from $33 at Truist
04/21/22 Piper Sandler
Range Resources upgraded to Overweight from Neutral at Piper Sandler
04/11/22 Benchmark
Range Resources price target raised to $43 from $33 at Benchmark
RRC Range Resources
$36.15 /

+1.4551 (+4.19%)

RRC Range Resources
$36.15 /

+1.4551 (+4.19%)

RRC Range Resources
$36.15 /

+1.4551 (+4.19%)

Syndicate
Immix Biopharma files to sell 1.68M shares of common stock » 17:03
05/27/22
05/27
17:03
05/27/22
17:03
IMMX

Immix Biopharma

$2.67 /

-0.33 (-11.00%)

ThinkEquity acted as sole…

ThinkEquity acted as sole book running manager for the offering.

ShowHide Related Items >><<
IMMX Immix Biopharma
$2.67 /

-0.33 (-11.00%)

  • 16
    Dec
IMMX Immix Biopharma
$2.67 /

-0.33 (-11.00%)

On The Fly
What You Missed On Wall Street On Friday » 16:39
05/27/22
05/27
16:39
05/27/22
16:39
GPS

Gap

$11.60 /

+0.45 (+4.04%)

, WDAY

Workday

$158.56 /

-9.5 (-5.65%)

, ULTA

Ulta Beauty

$425.30 /

+47.685 (+12.63%)

, DELL

Dell Technologies

$49.57 /

+5.715 (+13.03%)

, COST

Costco

$470.69 /

+5.37 (+1.15%)

, BOOT

Boot Barn

$81.74 /

+3.525 (+4.51%)

, ZS

Zscaler

$159.88 /

+17.55 (+12.33%)

, MRVL

Marvell

$60.83 /

+3.93 (+6.91%)

, BIG

Big Lots

$26.94 /

-3.71 (-12.11%)

, SIGA

Siga Technologies

$13.68 /

+4.04 (+41.91%)

, M

Macy's

$23.45 /

+0.525 (+2.29%)

, IQ

iQIYI

$3.98 /

+0.065 (+1.66%)

, UNH

UnitedHealth

$506.83 /

+4.43 (+0.88%)

, CGC

Canopy Growth

$4.87 /

-0.67 (-12.09%)

, RBGLY

Reckitt Benckiser

$15.65 /

-0.1601 (-1.01%)

, NAVI

Navient

$16.15 /

+0.435 (+2.77%)

, SOFI

SoFi Technologies

$7.56 /

+0.425 (+5.96%)

, NNI

Nelnet

$84.71 /

+0.41 (+0.49%)

, SLM

Sallie Mae

$19.49 /

+0.44 (+2.31%)

, DIDI

Didi

$2.02 /

+0.175 (+9.51%)

, TWTR

Twitter

$40.19 /

+0.66 (+1.67%)

, TSLA

Tesla

$759.79 /

+52.67 (+7.45%)

, FTCH

Farfetch

$9.73 /

+2.05 (+26.69%)

, PMVP

PMV Pharmaceuticals

$15.33 /

+2.11 (+15.96%)

, IOVA

Iovance Biotherapeutics

$7.01 /

-8.105 (-53.64%)

, MRTX

Mirati Therapeutics

$39.80 /

-18.63 (-31.88%)

, WEN

Wendy's

$18.84 /

+0.235 (+1.26%)

, HIBB

Hibbett

$52.49 /

+1.45 (+2.84%)

Get caught up quickly on…

ShowHide Related Items >><<
ZS Zscaler
$159.88 /

+17.55 (+12.33%)

WEN Wendy's
$18.84 /

+0.235 (+1.26%)

WDAY Workday
$158.56 /

-9.5 (-5.65%)

UNH UnitedHealth
$506.83 /

+4.43 (+0.88%)

ULTA Ulta Beauty
$425.30 /

+47.685 (+12.63%)

TWTR Twitter
$40.19 /

+0.66 (+1.67%)

TSLA Tesla
$759.79 /

+52.67 (+7.45%)

SOFI SoFi Technologies
$7.56 /

+0.425 (+5.96%)

SLM Sallie Mae
$19.49 /

+0.44 (+2.31%)

SIGA Siga Technologies
$13.68 /

+4.04 (+41.91%)

PMVP PMV Pharmaceuticals
$15.33 /

+2.11 (+15.96%)

NAVI Navient
$16.15 /

+0.435 (+2.77%)

MRVL Marvell
$60.83 /

+3.93 (+6.91%)

MRTX Mirati Therapeutics
$39.80 /

-18.63 (-31.88%)

M Macy's
$23.45 /

+0.525 (+2.29%)

IQ iQIYI
$3.98 /

+0.065 (+1.66%)

IOVA Iovance Biotherapeutics
$7.01 /

-8.105 (-53.64%)

HIBB Hibbett
$52.49 /

+1.45 (+2.84%)

GPS Gap
$11.60 /

+0.45 (+4.04%)

FTCH Farfetch
$9.73 /

+2.05 (+26.69%)

DIDI Didi
$2.02 /

+0.175 (+9.51%)

DELL Dell Technologies
$49.57 /

+5.715 (+13.03%)

COST Costco
$470.69 /

+5.37 (+1.15%)

CGC Canopy Growth
$4.87 /

-0.67 (-12.09%)

BOOT Boot Barn
$81.74 /

+3.525 (+4.51%)

BIG Big Lots
$26.94 /

-3.71 (-12.11%)

GPS Gap
$11.60 /

+0.45 (+4.04%)

05/27/22 UBS
Gap price target lowered to $11 from $14 at UBS
05/27/22 Deutsche Bank
Gap price target lowered to $12 from $17 at Deutsche Bank
05/27/22 Wells Fargo
Gap price target lowered to $16 from $20 at Wells Fargo
05/27/22 Baird
Gap price target lowered to $11 from $14 at Baird
WDAY Workday
$158.56 /

-9.5 (-5.65%)

05/27/22 DA Davidson
Workday price target lowered to $220 from $250 at DA Davidson
05/27/22 Stifel
Workday price target lowered to $220 from $275 at Stifel
05/27/22 BMO Capital
Workday price target lowered to $239 from $249 at BMO Capital
05/27/22 Needham
Workday price target lowered to $200 from $300 at Needham
ULTA Ulta Beauty
$425.30 /

+47.685 (+12.63%)

05/27/22 DA Davidson
Ulta Beauty price target raised to $465 from $450 at DA Davidson
05/27/22 Oppenheimer
Ulta Beauty price target raised to $485 from $470 at Oppenheimer
05/27/22 Jefferies
Jefferies upgrades Ulta Beauty to Buy after 'signal we'd been waiting for'
05/27/22 Baird
Ulta Beauty price target raised to $490 from $450 at Baird
DELL Dell Technologies
$49.57 /

+5.715 (+13.03%)

05/27/22 BofA
Dell Technologies price target raised to $67 from $65 at BofA
05/27/22 Morgan Stanley
Dell Technologies price target lowered to $56 from $60 at Morgan Stanley
05/27/22 Deutsche Bank
Dell Technologies price target lowered to $60 from $65 at Deutsche Bank
05/25/22 Evercore ISI
Dell Technologies added to 'Tactical Outperform' list at Evercore ISI
COST Costco
$470.69 /

+5.37 (+1.15%)

05/27/22 Truist
Costco price target raised to $543 from $503 at Truist
05/27/22 Baird
Costco price target lowered to $560 from $600 at Baird
05/27/22 Credit Suisse
Costco price target lowered to $550 from $570 at Credit Suisse
05/27/22 Loop Capital
Costco price target lowered to $610 from $650 at Loop Capital
BOOT Boot Barn
$81.74 /

+3.525 (+4.51%)

05/27/22 Baird
Boot Barn upgraded to Outperform from Neutral at Baird
05/11/22 Craig-Hallum
Boot Barn price target lowered to $145 from $162 at Craig-Hallum
05/11/22 JPMorgan
Boot Barn added to Analyst Focus List at JPMorgan
05/06/22 Piper Sandler
Boot Barn upgraded to Overweight from Neutral at Piper Sandler
ZS Zscaler
$159.88 /

+17.55 (+12.33%)

05/27/22 Cowen
Zscaler price target lowered to $194 from $405 at Cowen
05/27/22 Canaccord
Zscaler price target lowered to $210 from $320 at Canaccord
05/27/22 BMO Capital
Zscaler price target lowered to $172 from $270 at BMO Capital
05/27/22 Baird
Zscaler price target lowered to $200 from $300 at Baird
MRVL Marvell
$60.83 /

+3.93 (+6.91%)

05/27/22 BMO Capital
Marvell price target lowered to $82 from $98 at BMO Capital
05/27/22 Needham
Marvell price target lowered to $75 from $105 at Needham
05/27/22 BofA
Marvell price target lowered to $90 from $100 at BofA
05/27/22 Cowen
Marvell price target lowered to $85 from $100 at Cowen
BIG Big Lots
$26.94 /

-3.71 (-12.11%)

05/25/22 Deutsche Bank
Big Lots price target lowered to $31 from $44 at Deutsche Bank
05/24/22 BofA
Big Lots price target lowered to $25 from $31 at BofA
05/20/22 Piper Sandler
Big Lots price target lowered to $29 from $34 at Piper Sandler
05/10/22 JPMorgan
Big Lots price target lowered to $25 from $31 at JPMorgan
SIGA Siga Technologies
$13.68 /

+4.04 (+41.91%)

05/20/22 Benchmark
Benchmark says Emergent, Siga, Chimerix strength attributable to monkeypox scare
M Macy's
$23.45 /

+0.525 (+2.29%)

05/27/22 Deutsche Bank
Macy's price target lowered to $29 from $34 at Deutsche Bank
05/27/22 Citi
Macy's price target lowered to $23 from $25 at Citi
05/27/22 Morgan Stanley
Macy's upgraded to Equal Weight from Underweight at Morgan Stanley
05/16/22 JPMorgan
Macy's price target lowered to $30 from $33 at JPMorgan
IQ iQIYI
$3.98 /

+0.065 (+1.66%)

05/27/22 Benchmark
iQIYI upgraded to Buy from Hold at Benchmark
05/26/22 Citi
Citi upgrades iQIYI on earlier than expected profitability
05/26/22 Citi
iQIYI upgraded to Buy from Neutral at Citi
05/16/22 JPMorgan
iQIYI upgraded to Overweight from Underweight at JPMorgan
UNH UnitedHealth
$506.83 /

+4.43 (+0.88%)

05/26/22 Bernstein
UnitedHealth downgraded to Market Perform at Bernstein on valuation
05/26/22 Bernstein
UnitedHealth downgraded to Market Perform from Outperform at Bernstein
05/11/22 Citi
MultiPlan price target raised to $6.50 from $6 at Citi
04/26/22 Piper Sandler
Piper 'incrementally confident' Change, UNH will prevail in August
CGC Canopy Growth
$4.87 /

-0.67 (-12.09%)

05/27/22 Alliance Global Partners
Canopy Growth price target lowered to C$7 from C$8 at Alliance Global Partners
05/27/22 Benchmark
Canopy Growth cut to Sell at Benchmark after 'disappointing' quarter
05/27/22 Benchmark
Canopy Growth downgraded to Sell from Hold at Benchmark
05/20/22 Alliance Global Partners
Canopy Growth price target lowered to C$8 from C$11 at Alliance Global Partners
RBGLY Reckitt Benckiser
$15.65 /

-0.1601 (-1.01%)

05/18/22 RBC Capital
Reckitt Benckiser upgraded to Outperform from Sector Perform at RBC Capital
05/09/22 Morgan Stanley
Reckitt Benckiser price target raised to 7,100 GBp at Morgan Stanley
05/03/22 RBC Capital
Reckitt Benckiser price target raised to 5,900 GBp at RBC Capital
05/03/22 Barclays
Reckitt Benckiser price target raised to 9,300 GBp from 9,100 GBp at Barclays
NAVI Navient
$16.15 /

+0.435 (+2.77%)

04/11/22 JPMorgan
Navient cut to Underweight at JPMorgan on student lending normalization delay
04/11/22 JPMorgan
Navient downgraded to Underweight from Neutral at JPMorgan
03/31/22 Compass Point
Navient downgraded to Neutral from Buy at Compass Point
01/27/22 JPMorgan
Navient price target lowered to $21 from $23 at JPMorgan
SOFI SoFi Technologies
$7.56 /

+0.425 (+5.96%)

05/17/22 Mizuho
SoFi Technologies price target lowered to $9 from $14 at Mizuho
05/16/22 Piper Sandler
Piper upgrades SoFi to buy ahead of 'significant' earnings ramp
05/16/22 Piper Sandler
SoFi Technologies upgraded to Overweight from Neutral at Piper Sandler
05/12/22 Citi
SoFi Technologies price target lowered to $11 from $17 at Citi
NNI Nelnet
$84.71 /

+0.41 (+0.49%)

01/13/22 Credit Suisse
Nelnet downgraded to Neutral from Outperform at Credit Suisse
SLM Sallie Mae
$19.49 /

+0.44 (+2.31%)

05/02/22 Citi
Sallie Mae price target lowered to $21 from $26 at Citi
04/18/22 Stephens
Sallie Mae downgraded to Equal Weight from Overweight at Stephens
01/10/22 Barclays
Sallie Mae price target raised to $27 from $25 at Barclays
07/22/21 Stephens
Stephens 'surprised' by Sallie Mae stock underperformance, ups target to $23
DIDI Didi
$2.02 /

+0.175 (+9.51%)

03/16/22 US Tiger
China Internet sector upgraded to Outperform from Neutral at US Tiger
02/14/22 Bernstein
Didi initiated with an Outperform at Bernstein
07/28/21 Alliance Global Partners
Alliance Global Partners bullish on Aurora Mobile despite regulatory changes
07/28/21 Alliance Global Partners
iClick Interactive price target lowered to $15 from $21 at Alliance Global
TWTR Twitter
$40.19 /

+0.66 (+1.67%)

05/24/22 Jefferies
Twitter price target lowered to $40 from $48 at Jefferies
05/24/22 Wedbush
More fireworks expected heading into Twitter shareholder meeting, says Wedbush
05/24/22 KeyBanc
Snap price target lowered to $27 from $45 at KeyBanc
05/24/22 Bernstein
Bernstein says Tesla-Twitter saga far from over, discusses funding requirements
TSLA Tesla
$759.79 /

+52.67 (+7.45%)

05/27/22 Credit Suisse
Tesla pullback brings attractive entry point, says Credit Suisse
05/26/22 Jefferies
Jefferies cuts Tesla price target on governance risk, challenging market
FTCH Farfetch
$9.73 /

+2.05 (+26.69%)

05/27/22 Wedbush
Farfetch price target lowered to $8 from $16 at Wedbush
05/27/22 Morgan Stanley
Farfetch price target lowered to $30 from $56 at Morgan Stanley
05/27/22 Wells Fargo
Farfetch price target lowered to $25 from $35 at Wells Fargo
05/27/22 BTIG
Farfetch price target lowered to $16 from $26 at BTIG
PMVP PMV Pharmaceuticals
$15.33 /

+2.11 (+15.96%)

03/02/22 Oppenheimer
Oppenheimer upgrades PMV Pharmaceuticals to Outperform with $30 price target
03/02/22 Oppenheimer
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
09/22/21 Goldman Sachs
PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
08/19/21 Oppenheimer
PMV Pharmaceuticals initiated with a Perform at Oppenheimer
IOVA Iovance Biotherapeutics
$7.01 /

-8.105 (-53.64%)

05/27/22 H.C. Wainwright
Iovance Biotherapeutics 'close to the finish line,' says H.C. Wainwright
05/27/22 Oppenheimer
Iovance Biotherapeutics price target lowered to $27 from $31 at Oppenheimer
05/27/22 Stifel
Iovance Biotherapeutics after-hours stock reaction seems 'overdone,' says Stifel
05/27/22 Chardan
Iovance Biotherapeutics price target lowered to $31 from $44 at Chardan
MRTX Mirati Therapeutics
$39.80 /

-18.63 (-31.88%)

05/27/22 Stifel
Mirati Therapeutics after-hours move lower 'overdone,' says Stifel
05/20/22 Guggenheim
Guggenheim upgrades Mirati to Buy on adagrasib's 'highly competitive profile'
05/20/22 Guggenheim
Mirati Therapeutics upgraded to Buy from Neutral at Guggenheim
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
WEN Wendy's
$18.84 /

+0.235 (+1.26%)

05/25/22 MKM Partners
Wendy's may see more 'value unlocks' from strategic options, says MKM Partners
05/25/22 Wedbush
Wedbush remains bullish on Wendy's, not surprised by Trian news
05/25/22 Stifel
Wendy's deal in 'low-$20 range' would be 'feasible,' says Stifel
05/12/22 Truist
Wendy's price target lowered to $27 from $29 at Truist
HIBB Hibbett
$52.49 /

+1.45 (+2.84%)

05/27/22 Baird
Hibbett price target lowered to $70 from $75 at Baird
03/07/22 Benchmark
Hibbett price target lowered to $80 from $125 at Benchmark
02/22/22 Monness Crespi
Hibbett price target lowered to $80 from $120 at Monness Crespi
02/21/22 Baird
Hibbett price target lowered to $75 from $100 at Baird
ZS Zscaler
$159.88 /

+17.55 (+12.33%)

WEN Wendy's
$18.84 /

+0.235 (+1.26%)

WDAY Workday
$158.56 /

-9.5 (-5.65%)

UNH UnitedHealth
$506.83 /

+4.43 (+0.88%)

ULTA Ulta Beauty
$425.30 /

+47.685 (+12.63%)

TWTR Twitter
$40.19 /

+0.66 (+1.67%)

TSLA Tesla
$759.79 /

+52.67 (+7.45%)

SOFI SoFi Technologies
$7.56 /

+0.425 (+5.96%)

SLM Sallie Mae
$19.49 /

+0.44 (+2.31%)

SIGA Siga Technologies
$13.68 /

+4.04 (+41.91%)

PMVP PMV Pharmaceuticals
$15.33 /

+2.11 (+15.96%)

NAVI Navient
$16.15 /

+0.435 (+2.77%)

MRVL Marvell
$60.83 /

+3.93 (+6.91%)

MRTX Mirati Therapeutics
$39.80 /

-18.63 (-31.88%)

M Macy's
$23.45 /

+0.525 (+2.29%)

IQ iQIYI
$3.98 /

+0.065 (+1.66%)

IOVA Iovance Biotherapeutics
$7.01 /

-8.105 (-53.64%)

HIBB Hibbett
$52.49 /

+1.45 (+2.84%)

GPS Gap
$11.60 /

+0.45 (+4.04%)

FTCH Farfetch
$9.73 /

+2.05 (+26.69%)

DIDI Didi
$2.02 /

+0.175 (+9.51%)

DELL Dell Technologies
$49.57 /

+5.715 (+13.03%)

COST Costco
$470.69 /

+5.37 (+1.15%)

CGC Canopy Growth
$4.87 /

-0.67 (-12.09%)

BOOT Boot Barn
$81.74 /

+3.525 (+4.51%)

BIG Big Lots
$26.94 /

-3.71 (-12.11%)

  • 16
    Nov
  • 11
    Nov
  • 30
    Jun
ZS Zscaler
$159.88 /

+17.55 (+12.33%)

WEN Wendy's
$18.84 /

+0.235 (+1.26%)

WDAY Workday
$158.56 /

-9.5 (-5.65%)

UNH UnitedHealth
$506.83 /

+4.43 (+0.88%)

TWTR Twitter
$40.19 /

+0.66 (+1.67%)

TSLA Tesla
$759.79 /

+52.67 (+7.45%)

RBGLY Reckitt Benckiser
$15.65 /

-0.1601 (-1.01%)

PMVP PMV Pharmaceuticals
$15.33 /

+2.11 (+15.96%)

NNI Nelnet
$84.71 /

+0.41 (+0.49%)

NAVI Navient
$16.15 /

+0.435 (+2.77%)

M Macy's
$23.45 /

+0.525 (+2.29%)

IQ iQIYI
$3.98 /

+0.065 (+1.66%)

HIBB Hibbett
$52.49 /

+1.45 (+2.84%)

GPS Gap
$11.60 /

+0.45 (+4.04%)

DIDI Didi
$2.02 /

+0.175 (+9.51%)

DELL Dell Technologies
$49.57 /

+5.715 (+13.03%)

CGC Canopy Growth
$4.87 /

-0.67 (-12.09%)

ZS Zscaler
$159.88 /

+17.55 (+12.33%)

WEN Wendy's
$18.84 /

+0.235 (+1.26%)

WDAY Workday
$158.56 /

-9.5 (-5.65%)

ULTA Ulta Beauty
$425.30 /

+47.685 (+12.63%)

TWTR Twitter
$40.19 /

+0.66 (+1.67%)

TSLA Tesla
$759.79 /

+52.67 (+7.45%)

SOFI SoFi Technologies
$7.56 /

+0.425 (+5.96%)

SIGA Siga Technologies
$13.68 /

+4.04 (+41.91%)

NAVI Navient
$16.15 /

+0.435 (+2.77%)

MRVL Marvell
$60.83 /

+3.93 (+6.91%)

MRTX Mirati Therapeutics
$39.80 /

-18.63 (-31.88%)

M Macy's
$23.45 /

+0.525 (+2.29%)

IQ iQIYI
$3.98 /

+0.065 (+1.66%)

IOVA Iovance Biotherapeutics
$7.01 /

-8.105 (-53.64%)

HIBB Hibbett
$52.49 /

+1.45 (+2.84%)

GPS Gap
$11.60 /

+0.45 (+4.04%)

FTCH Farfetch
$9.73 /

+2.05 (+26.69%)

DIDI Didi
$2.02 /

+0.175 (+9.51%)

DELL Dell Technologies
$49.57 /

+5.715 (+13.03%)

COST Costco
$470.69 /

+5.37 (+1.15%)

CGC Canopy Growth
$4.87 /

-0.67 (-12.09%)

BOOT Boot Barn
$81.74 /

+3.525 (+4.51%)

BIG Big Lots
$26.94 /

-3.71 (-12.11%)

ZS Zscaler
$159.88 /

+17.55 (+12.33%)

WEN Wendy's
$18.84 /

+0.235 (+1.26%)

WDAY Workday
$158.56 /

-9.5 (-5.65%)

UNH UnitedHealth
$506.83 /

+4.43 (+0.88%)

ULTA Ulta Beauty
$425.30 /

+47.685 (+12.63%)

TWTR Twitter
$40.19 /

+0.66 (+1.67%)

TSLA Tesla
$759.79 /

+52.67 (+7.45%)

SOFI SoFi Technologies
$7.56 /

+0.425 (+5.96%)

SIGA Siga Technologies
$13.68 /

+4.04 (+41.91%)

NAVI Navient
$16.15 /

+0.435 (+2.77%)

MRVL Marvell
$60.83 /

+3.93 (+6.91%)

M Macy's
$23.45 /

+0.525 (+2.29%)

IQ iQIYI
$3.98 /

+0.065 (+1.66%)

IOVA Iovance Biotherapeutics
$7.01 /

-8.105 (-53.64%)

GPS Gap
$11.60 /

+0.45 (+4.04%)

FTCH Farfetch
$9.73 /

+2.05 (+26.69%)

DIDI Didi
$2.02 /

+0.175 (+9.51%)

DELL Dell Technologies
$49.57 /

+5.715 (+13.03%)

COST Costco
$470.69 /

+5.37 (+1.15%)

CGC Canopy Growth
$4.87 /

-0.67 (-12.09%)

BOOT Boot Barn
$81.74 /

+3.525 (+4.51%)

BIG Big Lots
$26.94 /

-3.71 (-12.11%)

Syndicate
Metalla Royalty & Streaming announces updated at-the-market program for $50M » 16:37
05/27/22
05/27
16:37
05/27/22
16:37
MTA

Metalla Royalty & Streaming

$5.62 /

+0.175 (+3.21%)

Metalla Royalty &…

Metalla Royalty & Streaming is pleased to announce that it has entered into a new equity distribution agreement with a syndicate of agents including BMO Nesbitt Burns Inc., PI Financial Corp., and Scotia Capital Inc., as the Canadian agents, and BMO Capital Markets Corp. and Scotia Capital Inc., as the United States agents, for a new at-the-market equity program. The Distribution Agreement will allow the Company to distribute up to $50 million of common shares of the Company under the 2022 ATM Program. The Offered Shares will be issued by the Company to the public from time to time, through the Agents, at the Company's discretion. The Offered Shares sold under the 2022 ATM Program, if any, will be sold at the prevailing market price at the time of sale.

ShowHide Related Items >><<
MTA Metalla Royalty & Streaming
$5.62 /

+0.175 (+3.21%)

MTA Metalla Royalty & Streaming
$5.62 /

+0.175 (+3.21%)

09/16/21 Scotiabank
Metalla Royalty & Streaming initiated with a Sector Perform at Scotiabank
Initiation
BNP Paribas initiated with Not Rated at Goldman Sachs » 16:37
05/27/22
05/27
16:37
05/27/22
16:37
BNPQY

BNP Paribas

$28.95 /

+0.585 (+2.06%)

Goldman Sachs analyst…

Goldman Sachs analyst Chris Hallam initiated coverage of BNP Paribas with Not Rated.

ShowHide Related Items >><<
BNPQY BNP Paribas
$28.95 /

+0.585 (+2.06%)

BNPQY BNP Paribas
$28.95 /

+0.585 (+2.06%)

05/25/22 Deutsche Bank
BNP Paribas price target raised to EUR 66 from EUR 64 at Deutsche Bank
05/05/22 UBS
BNP Paribas price target raised to EUR 63 from EUR 60 at UBS
05/05/22 JPMorgan
BNP Paribas price target raised to EUR 62 from EUR 61 at JPMorgan
05/04/22 Barclays
BNP Paribas price target raised to EUR 64.30 from EUR 62.30 at Barclays
BNPQY BNP Paribas
$28.95 /

+0.585 (+2.06%)

BNPQY BNP Paribas
$28.95 /

+0.585 (+2.06%)

Initiation
Societe Generale initiated with a Neutral at Goldman Sachs » 16:36
05/27/22
05/27
16:36
05/27/22
16:36
SCGLY

Societe Generale

$5.40 /

+0.02 (+0.37%)

Goldman Sachs analyst…

Goldman Sachs analyst Chris Hallam initiated coverage of Societe Generale with a Neutral rating and EUR 35 price target. The analyst believes the company "should see growth supported in the coming years by higher interest rates in the traditional banking business and elevated activity levels in Global Markets," however he adds that the company is "not as geared to rates as peers, consensus estimates already imply Global Markets revenue targets will be exceeded and Boursorama's success will make a relatively small impact at a group level over 2023/24."

ShowHide Related Items >><<
SCGLY Societe Generale
$5.40 /

+0.02 (+0.37%)

SCGLY Societe Generale
$5.40 /

+0.02 (+0.37%)

05/25/22 RBC Capital
Societe Generale price target raised to EUR 32 from EUR 29 at RBC Capital
05/19/22 JPMorgan
Societe Generale price target raised to EUR 33 from EUR 29 at JPMorgan
05/19/22 Keefe Bruyette
Societe Generale upgraded on Russia assets sale at Keefe Bruyette
05/18/22 Keefe Bruyette
Societe Generale upgraded to Outperform from Market Perform at Keefe Bruyette

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.